UniQure stock is rated a Buy with a $66 price target, offering upside after recent FDA pushback on AMT-130 Huntington's therapy trial design. AMT-130 is the first disease-modifying therapy for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback